Table 2. Changes in measurements after 12 weeks of treatment with sodium-glucose cotransporter-2 inhibitors.
| Variable | Baseline | Week 12 | LS mean change from baseline (95% CI) | Difference in LS mean change (95% CI)a |
|---|---|---|---|---|
| HbA1c, % | ||||
| Overall (n=410) | 8.5±0.1 | 7.8±0.1 | −0.68 (−0.78 to −0.58)b | −0.52 (−0.68 to −0.37)c |
| Add-on (n=207) | 8.6±0.1 | 7.6±0.1 | −0.94 (−1.05 to −0.83)b | |
| Switch (n=203) | 8.4±0.1 | 8.0±0.1 | −0.42 (−0.53 to −0.30)b | |
| FPG, mg/dL | ||||
| Overall (n=410) | 156.6±2.1 | 131.5±1.6 | −25.1 (−29.5 to −20.8)b | −10.5 (−16.6 to −4.4)c |
| Add-on (n=207) | 164.8±2.9 | 128.5±2.2 | −30.3 (−34.6 to −26.1)b | |
| Switch (n=203) | 148.4±2.9 | 134.5±2.3 | −19.8 (−24.1 to −15.6)b | |
| TG, mg/dL | ||||
| Overall (n=410) | 157.0±5.1 | 140.6±3.7 | −16.5 (−24.2 to −8.7)b | −2.7 (−14.0 to 8.5) |
| Add-on (n=207) | 160.8±8.1 | 141.0±5.3 | −17.8 (−25.6 to −9.9)b | |
| Switch (n=203) | 153.1±6.0 | 140.1±5.3 | −15.1 (−23.1 to −7.1)b | |
| HDL-C, mg/dL | ||||
| Overall (n=410) | 45.4±0.6 | 45.8±0.5 | 0.5 (−0.3 to −1.2) | 0.6 (−0.8 to 2.0) |
| Add-on (n=207) | 45.7±0.8 | 46.4±0.7 | 0.8 (−0.2 to 1.7) | |
| Switch (n=203) | 45.0±0.8 | 45.2±0.8 | 0.1 (−0.8 to 1.1) | |
| LDL-C, mg/dL | ||||
| Overall (n=410) | 82.4±1.2 | 80.5±1.3 | −1.9 (−4.1 to 0.3) | 2.0 (−2.0 to 6.0) |
| Add-on (n=207) | 81.6±1.6 | 81.0±1.7 | −0.9 (−3.7 to 1.9) | |
| Switch (n=203) | 83.2±1.9 | 80.0±1.9 | −2.9 (−5.8 to 0.1) | |
| Body weight, kg | ||||
| Overall (n=410) | 74.6±1.2 | 72.5±1.1 | −2.1 (−2.4 to −1.7)b | 0.5 (−0.3 to 1.1) |
| Add-on (n=207) | 74.1±1.5 | 72.3±1.5 | −1.9 (−2.4 to −1.5)b | |
| Switch (n=203) | 75.2±1.8 | 72.8±1.7 | −2.4 (−2.8 to −1.9)b | |
| SBP, mm Hg | ||||
| Overall (n=410) | 130.1±0.7 | 125.4±0.7 | −4.7 (−6.1 to −3.3)b | 1.1 (−1.3 to 3.5) |
| Add-on (n=207) | 131.3±1.0 | 126.5±1.0 | −4.2 (−5.9 to −2.6)b | |
| Switch (n=203) | 128.8±1.0 | 124.2±1.0 | −5.3 (−7.0 to −3.6)b | |
| DBP, mm Hg | ||||
| Overall (n=410) | 78.7±0.7 | 77.3±1.0 | −1.3 (−2.4 to −0.2)b | 0.6 (−1.4 to 2.7) |
| Add-on (n=207) | 78.4±0.7 | 77.1±1.0 | −1.0 (−2.5 to 0.4) | |
| Switch (n=203) | 76.5±0.7 | 75.3±0.7 | −1.7 (−3.2 to −0.2) | |
| eGFR, mL/min/1.73 m2 | ||||
| Overall (n=410) | 91.4±1.2 | 91.8±1.2 | 0.4 (−1.0 to 1.8) | −1.9 (−4.7 to 0.8) |
| Add-on (n=207) | 91.9±1.6 | 91.3±1.6 | −0.6 (−2.6 to 1.4) | |
| Switch (n=203) | 90.8±1.7 | 92.3±1.8 | 1.5 (−0.4 to 3.5) |
Values are presented as mean±standard error.
LS, least square; CI, confidence interval; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate.
aDifference in the LS mean change, which was calculated as add-on therapy minus switch therapy, bP<0.05 from baseline in overall patients and each treatment group, cP<0.05 for the between-treatment group difference.